Truist Financial Corp Neurocrine Biosciences Inc Transaction History

Truist Financial Corp

$62.9 Billion
Q3 2024

A detailed history of Truist Financial Corp transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Truist Financial Corp holds 214,283 shares of NBIX stock, worth $26.9 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

214,283

Previous 31,546 579.27%

Holding current value

$26.9 Million

Previous $4.34 Million 468.17%

% of portfolio

0.04%

Previous 0.01%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$114.58 - $153.15 $20.9 Million - $28 Million	182,737 Added 579.27%	214,283 $24.7 Million
Q2 2024 Aug 20, 2024	SELL	$130.86 - $143.19 $759,249 - $830,788	-5,802 Reduced 15.53%	31,546 $4.34 Million
Q1 2024 May 10, 2024	BUY	$130.4 - $143.74 $19,951 - $21,992	153 Added 0.41%	37,348 $5.15 Million
Q4 2023 Feb 02, 2024	BUY	$106.07 - $132.76 $150,937 - $188,917	1,423 Added 3.98%	37,195 $4.9 Million
Q3 2023 Nov 14, 2023	BUY	$94.02 - $117.1 $39,018 - $48,596	415 Added 1.17%	35,772 $4.02 Million
Q2 2023 Aug 01, 2023	SELL	$89.53 - $104.87 $559,920 - $655,856	-6,254 Reduced 15.03%	35,357 $3.33 Million
Q1 2023 May 05, 2023	SELL	$94.11 - $123.02 $68,417 - $89,435	-727 Reduced 1.72%	41,611 $4.21 Million
Q4 2022 Feb 17, 2023	SELL	$106.72 - $127.06 $184,732 - $219,940	-1,731 Reduced 3.93%	42,338 $5.06 Million
Q3 2022 Oct 26, 2022	SELL	$92.03 - $107.81 $571,506 - $669,500	-6,210 Reduced 12.35%	44,069 $4.68 Million
Q2 2022 Jul 22, 2022	SELL	$75.79 - $100.07 $831,113 - $1.1 Million	-10,966 Reduced 17.91%	50,279 $4.9 Million
Q1 2022 Apr 22, 2022	BUY	$72.45 - $94.81 $1.32 Million - $1.73 Million	18,226 Added 42.37%	61,245 $5.74 Million
Q4 2021 Feb 14, 2022	SELL	$79.65 - $106.22 $179,770 - $239,738	-2,257 Reduced 4.98%	43,019 $3.66 Million
Q3 2021 Nov 05, 2021	BUY	$86.18 - $99.03 $152,624 - $175,382	1,771 Added 4.07%	45,276 $4.34 Million
Q2 2021 Aug 16, 2021	SELL	$89.43 - $102.27 $211,412 - $241,766	-2,364 Reduced 5.15%	43,505 $4.23 Million
Q1 2021 May 17, 2021	BUY	$87.57 - $119.4 $168,572 - $229,845	1,925 Added 4.38%	45,869 $4.46 Million
Q4 2020 Nov 19, 2021	SELL	$86.91 - $108.33 $288,888 - $360,088	-3,324 Reduced 7.03%	43,944 $4.21 Million
Q4 2020 Feb 18, 2021	BUY	$86.91 - $108.33 $237,264 - $295,740	2,730 Added 6.13%	47,268 $4.53 Million
Q3 2020 Nov 13, 2020	BUY	$96.16 - $135.15 $305,019 - $428,695	3,172 Added 7.67%	44,538 $4.28 Million
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $47,905 - $73,392	563 Added 1.38%	41,366 $5.05 Million
Q1 2020 May 15, 2020	BUY	$75.11 - $113.76 $451,035 - $683,128	6,005 Added 17.26%	40,803 $3.53 Million
Q4 2019 Feb 14, 2020	BUY	$86.8 - $118.57 $3.02 Million - $4.13 Million	34,798 New	34,798 $3.74 Million

Others Institutions Holding NBIX

# of Institutions

629

Shares Held

94.2M

Call Options Held

692K

Put Options Held

406K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Truist Financial Corp with notifications on news.

Account

Truist Financial Corp Neurocrine Biosciences Inc Transaction History